@FierceMedDev: Adaptive Biotechnologies reels in $195M for immunosequencing tech. FierceDiagnostics story | Follow @FierceMedDev
@VarunSaxena2: ICYMI yesterday: Smith & Nephew boosts rep-less sales pilot by acquiring software assets that help automate training. Article | Follow @VarunSaxena2
@EmilyWFierce: ICYMI: RainDance shoots for long reads of whole genome with Pac Bio collaboration. Item | Follow @EmilyWFierce
> Boston Scientific ($BSX) has raised $1.85 billion in debt to help financing the acquisition of the urology device portfolio from Endo International ($ENDP) for $1.6 billion. The transaction is still slated to close next quarter. More
> L'Oreal USA has partnered with 3-D bioprinting company Organovo Holdings to create 3-D printed skin tissue for product evaluation and other areas of advanced research. More
> A MarketWatch opinion piece suggests that Apple Watch and other wearables are experiencing rapid adoption among physicians. More
Biotech News
@FierceBiotech: La Jolla dumps its NASH drug and shifts its focus to rare disease. Report | Follow @FierceBiotech
@JohnCFierce: My thought: FDA panels lean on the side of approval, especially for a disease like CF. Any ??? can be answered post approval. $VRTX wins. | Follow @JohnCFierce
> MorphoSys bags a peptide biotech for $22M. Item
> FDA review challenges Vertex's case for crucial cystic fibrosis combo. Article
> Phase I safety scare costs TetraLogic a $25M fundraise. News
Pharma News
@FiercePharma: Japan's Eisai makes moves for Indian API manufacturing in further cost trimming. FiercePharmaAsia story | Follow @FiercePharma
@CarlyHFierce: ICYMI: Valeant chief Pearson the next Warren Buffett? Deal partner Ackman thinks so. Story | Follow @CarlyHFierce
> FDA staffers raise doubts over key Vertex combo. Story
> AdverseEvents: New generation of hep C meds bests older therapies in side-effect reports. More
> Amarin sues FDA over 'free speech' issue the agency says it is ready to hash out. Article